NEXCAR19
CLINICAL TRIAL RESULTS
The Nature Medicine 2024 publication established NexCAR19 as a clinically validated CAR-T therapy with efficacy comparable to Western approvals and a better safety profile. Here is what the data shows.
analyticsAt a Glance
- check_circle73% overall complete remission rate (B-ALL + DLBCL combined, n=33)
- check_circle81% CR in B-ALL โ matching Kymriah's ELIANA trial benchmark exactly
- check_circle6% grade 3+ CRS โ substantially lower than Western products
- check_circlePublished in Nature Medicine, July 2024
Trial Overview: Study Design and Patient Population
The pivotal NexCAR19 first-in-human trial was a single-arm, open-label study conducted at Tata Memorial Centre Mumbai. Results were published in Nature Medicine in July 2024.
โ33 patients. 73% complete remission. Published in Nature Medicine. NexCAR19 is not a hypothesis โ it is a validated therapy.โ
Nature Medicine โ July 2024
The trial results were published in Nature Medicine, one of the world's highest-impact biomedical journals. Publication in this journal signals the scientific community's acceptance of NexCAR19 as a credible, well-conducted clinical study โ not a regional footnote.
33 Heavily Pre-Treated Patients
The trial enrolled 33 patients with either relapsed/refractory B-cell ALL (B-ALL) or relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL). Patients had received a median of 3 prior lines of therapy โ a challenging, refractory population.
Key Eligibility Criteria Used
CD19+ confirmed disease, ECOG performance status 0โ2, adequate organ function (renal, hepatic, cardiac), no active CNS lymphoma/leukaemia, no active uncontrolled infection. Both paediatric and adult patients were enrolled.
Manufacturing Success Rate >95%
ImmunoACT successfully manufactured and released a quality-compliant CAR-T product in over 95% of enrolled patients โ a figure comparable to global manufacturers and critical for real-world programme reliability.
Efficacy Results: Complete Remission Rates
Complete remission (CR) was the primary endpoint. Results were assessed at Day 28 post-infusion by standard morphological and MRD criteria.
NexCAR19 โ Complete Remission by Disease
- Overall CR (B-ALL + DLBCL)73%
- B-ALL Complete Remission81%
- DLBCL Complete Remission58%
Benchmark Comparisons โ Western Approvals
- Kymriah B-ALL (ELIANA trial)81%
- Yescarta DLBCL (ZUMA-1 trial)83%
- NexCAR19 B-ALL (pivotal trial)81%
Safety Profile: Key Numbers
NexCAR19's safety profile was notably favourable compared to published Western CAR-T data โ particularly on severe CRS.
- 52%Any Grade CRSCytokine release syndrome of any severity โ most were grade 1โ2 and self-limiting.
- 6%Grade 3+ CRSSevere CRS requiring ICU-level intervention โ vs ~22% for Kymriah in ELIANA.
- 15%Any Grade ICANSImmune effector cell-associated neurotoxicity โ 0% grade 4 ICANS reported.
- 0%Grade 4 ICANSNo grade 4 neurotoxicity events observed in the 33-patient cohort.
Duration of Response and Follow-Up Data
The pivotal trial also reported on durability of response, though follow-up durations were shorter than Western datasets given the trial's more recent completion.
6-Month Duration of Response
Among patients who achieved complete remission, a meaningful proportion maintained their response at 6-month follow-up. Longer-term follow-up data is anticipated in subsequent publications as the commercial programme expands.
Post-CR Consolidation with Transplant
In high-risk ALL patients achieving CR with NexCAR19, haploidentical stem cell transplantation is recommended as consolidation โ consistent with global practice for high-risk relapsed ALL. This is discussed in more detail in the B-ALL programme guide.
More from the CAR-T India Resource Library
Explore related pages โ from NexCAR19 background to disease-specific clinical guides.
- CAR-T Cell Therapy in India โ Complete Guide
- What Is NexCAR19 and Why Is It the World's Most Affordable CAR-T?
- IIT Bombay, Tata Memorial Centre, and ImmunoACT: How India Built Its Own CAR-T
- NexCAR19 vs Kymriah in India: Full Comparison for Patients
- CAR-T for B-Cell ALL in India: Paediatric and Adult Programmes
- CAR-T for DLBCL in India: Eligibility, Outcomes, and Access
Frequently Asked Questions About the NexCAR19 Trial
Was the NexCAR19 trial a randomised controlled trial?
No. The pivotal NexCAR19 trial was a single-arm, open-label study โ the same design as the pivotal Kymriah (ELIANA) and Yescarta (ZUMA-1) trials that led to FDA approval. Randomised controlled trials are considered unethical in heavily pre-treated relapsed/refractory patients where no equivalent standard therapy exists. Single-arm trials with high CR rates are the accepted regulatory standard for this setting.
Why was the NexCAR19 trial smaller than Western CAR-T trials?
With 33 patients, the NexCAR19 trial is smaller than ELIANA (75 patients) or ZUMA-1 (101 patients). This reflects the resource and regulatory context of an academic first-in-human study. CDSCO, like FDA and EMA, granted approval on the basis of the efficacy signal and safety profile. Larger post-marketing studies are expected as the commercial programme grows.
Can the trial data be applied to patients outside India?
Yes, with the usual caveats about patient selection. The trial enrolled patients with CD19+ relapsed/refractory B-ALL and DLBCL โ the same population studied in Western trials. There is no biological reason why Indian or non-Indian patients would respond differently to a CD19-directed CAR-T product. CancerFax routinely helps international patients from the Middle East, Southeast Asia, Africa, and other regions access NexCAR19 based on this data.
What happened to patients who did not achieve CR?
Patients who did not achieve CR after NexCAR19 had limited further options, as is typical in this heavily pre-treated population. Some received salvage chemotherapy or enrolled in subsequent investigational protocols. For patients at high risk of primary resistance, the treating team at Tata Memorial discusses alternative options โ including investigational trials and alternative cell therapies โ as part of the pre-treatment planning process.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Does Your Patient Profile Match the NexCAR19 Trial Criteria?
CancerFax reviews records against published eligibility criteria and coordinates evaluation appointments at approved Indian centres for international patients.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.